Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.55 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.50 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.50 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.48 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Endothelin SCHEMBL29352622 | 0.97 | KCNMA1 (0.53) | KCNMA1KCNMB4RXFP4RXFP3SSTR2 | |
| SCHEMBL26929028 | 0.95 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP4RXFP3SSTR2 | |
| SCHEMBL29403556 | 0.95 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP4RXFP3SSTR2 | |
| Endothelin SCHEMBL29403065 | 0.91 | RXFP1 (0.55) | KCNMA1KCNMB4RXFP4RXFP3RXFP1 | |
| Endothelin SCHEMBL21644373 | 0.91 | RXFP1 (0.55) | KCNMA1KCNMB4RXFP4RXFP3RXFP1 | |
| SCHEMBL29484633 | 0.90 | KCNMA1 (0.55) | KCNMA1KCNMB4RXFP4RXFP3RXFP1 | |
| SCHEMBL29661263 | 0.89 | KCNMA1 (0.55) | KCNMA1KCNMB4SSTR2SSTR5RXFP1 | |
| SCHEMBL29921568 | 0.87 | KCNMA1 (0.54) | KCNMA1KCNMB4RXFP4RXFP3RXFP1 | |
| SCHEMBL21412610 | 0.81 | IL23R (0.58) | KCNMA1KCNMB4RXFP3SSTR2SSTR5 | |
| SCHEMBL21412615 | 0.81 | IL23R (0.58) | KCNMA1KCNMB4RXFP3SSTR2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460177-B2 | Composition for promoting efficiency of somatic cell replication | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2025-11-04 | — | — | US | claimed |
| WO-2024232849-A1 | A PHARMACEUTICAL COMPOSITION FOR INCREASING MELANIN SYNTHESIS IN HAIR FOLLICLES | IFL PHARMA ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-11-14 | — | — | WO | claimed |
| US-11450431-B2 | Method to identify optimum coronary artery disease treatment | SIEMENS HEALTHCARE GMBH (DE) | 2022-09-20 | — | — | US | claimed |
| US-20260109760-A1 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | FATHER FLANAGANS BOYS HOME DOING BUSINESS AS BOYS TOWN NATIONAL RES HOSPITAL (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4715043-A1 | METHOD FOR PRODUCING NEURAL CREST CELLS | Kyoto University (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | ASTELLAS PHARMA INC. (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4673949-A1 | A METHOD FOR DETERMINING A STAGE OF AN EPIGENETIC PROPERTY OF AN EPIDERMIS | Mitra Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| EP-4149556-B1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12516083-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-06 | — | — | US | disclosed |
| EP-2849795-B1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | TAKEDA PHARMACEUTICALS CO (JP) | 2022-04-06 | — | — | EP | disclosed |
| CN-106459160-B | ASX-specific protein ligases | 南洋理工大学 | 2022-03-29 | — | — | CN | disclosed |
| US-11278748-B2 | Endothelin-converting enzyme inhibitor | KAO CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-114085810-A | Preparation method of similar mesenchymal stem cells and similar mesenchymal stem cells prepared by same | 株式会社未来细胞生物 | 2022-02-25 | — | — | CN | disclosed |
| CN-112245363-B | Salvia miltiorrhiza whitening and freckle removing mask | 山东农业大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-109846762-B | Composition with whitening effect and preparation method and application thereof | 上海珈凯生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060221-A1 | METHOD FOR PRODUCING NONHUMAN PRIMATE ANIMAL MODEL OF CEREBRAL INFARCTION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CEREBRAL INFARCTION | FABP7, NES, VEGFA | KCNMA1 3134/4885KCNMB4 3272/4885RXFP4 2585/4885 |
| US-20260109760-A1 | NEUTRALIZING ANTIBODIES TO HUMAN ENDOTHELIN | ETV1, CDR2, IGLV6-57 | KCNMA1 1850/4885KCNMB4 2497/4885RXFP4 2416/4885 |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | KCNMA1 1926/4885KCNMB4 2675/4885RXFP4 4138/4885 |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | IGLV6-57, ETV1, VEGFA | KCNMA1 1666/4885KCNMB4 1594/4885RXFP4 1751/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | KCNMA1 4494/4885KCNMB4 4266/4885RXFP4 4470/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | KCNMA1 4708/4885KCNMB4 4633/4885RXFP4 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.